Johnson & Johnson $JNJ Stake Lessened by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group L.P. has significantly reduced its stake in Johnson & Johnson, selling 700,342 shares and now owning only 133,727 shares, worth approximately $22.18 million.
• Johnson & Johnson reported a quarterly EPS of $2.77, exceeding analysts' expectations, with revenues of $23.74 billion, representing a year-over-year increase of 5.8%.
• The company will pay a quarterly dividend of $1.30 on September 9th, reflecting an annualized yield of 2.9% with a payout ratio of 55.61%.

Alyeska Investment Group L.P. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 84.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 133,727 shares of the company's stock after selling 700,342 shares during the period. Alyeska Investment Group L.P.'s holdings in Johnson & Johnson were worth $22,177,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Highline Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter worth $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.4%

Shares of JNJ opened at $178.64 on Friday. The stock has a market cap of $430.23 billion, a price-to-earnings ratio of 19.11, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a 50-day moving average price of $168.06 and a two-hundred day moving average price of $160.60.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Guggenheim reaffirmed a "neutral" rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.